相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association
Connie W. Tsao et al.
CIRCULATION (2022)
Newer Glucose-Lowering Drugs and Risk of Dementia: A Meta-analysis of Cardiovascular Outcome Trials
Huilin Tang et al.
DIABETES (2022)
GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
Yi-Sun Yang et al.
DIABETES CARE (2022)
Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population
Ana M. Cebrian-Cuenca et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Maria Ida Maiorino et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Christine Rode Andreasen et al.
DIABETES OBESITY & METABOLISM (2021)
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Donna Shu-Han Lin et al.
DIABETOLOGIA (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Current advances in ischemic stroke research and therapies
Derek Barthels et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)
Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials
Soo Lim et al.
DIABETES OBESITY & METABOLISM (2020)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies
Ida R. Marlet et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking
E. Ramirez et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
Soojin Kim et al.
EXPERIMENTAL NEUROBIOLOGY (2017)
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Alison Cameron-Vendrig et al.
DIABETES (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways
Lili Shi et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
Xiaoyan Song et al.
SCIENTIFIC REPORTS (2015)
Anorexia and Impaired Glucose Metabolism in Mice With Hypothalamic Ablation of Glut4 Neurons
Hongxia Ren et al.
DIABETES (2015)
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
Andrew E. Hogan et al.
DIABETOLOGIA (2014)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats
Gisele Giannocco et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Kenichiro Sato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
An Updated Definition of Stroke for the 21st Century A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Ralph L. Sacco et al.
STROKE (2013)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A
Hisko Oeseburg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Immunohistochemical localization and quantification of glucose transporters in the mouse brain
C Choeiri et al.
NEUROSCIENCE (2002)
分享论文
